Value of CT radiomics in discrimination of hypervascular adrenal adenoma from pheochromocytoma
CHENG Yuanhua1, LU Jing2, HUA Rongrong2, HE Xucheng2, ZHANG Yanan2, WANG Guisheng2, CHEN Xiaoxia2
1. Department of Radiology, Xuanhan People's Hospital of Sichuan Province,636150; 2. Department of Radiology, the Third Medical Center of PLA General Hospital, Beijing 100039, China
AbstractObjective To explore the value of the CT radiomics model in the differential diagnosis of hypervascular adrenal adenoma (HAA) and pheochromocytoma (AP). Methods A total of 79 patients (53 HAA and 26 AP) who underwent phase 4 CT scan and were pathologically confirmed in the Department of Radiology of the Third Medical Center of PLA General Hospital from January 2022 to July 2024 were retrospectively included. Clinical indicators and radiomics features extracted from CT images through scientific research platform were analyzed. Using the F_Test to reduce dimensionality and screen radiomics features, factors with statistically significant differences were included in binary logistic regression analysis and subsequent modeling. Finally, ROC curve and decision curve of the predictive model were plotted to evaluate its predictive performance and clinical application value. Results The value of plain CT scan (OR=1.166, P<0.01) and the long diameter of tumor (OR=2.226, P<0.01) were independent risk factors for the discrimination of the two groups. The AUC based on CTpre, arterial phase (CTa), late arterial phase (CTla), venous phase (CTv), four-phase combination, imaging features, and clinical indicator model validation set were 0.93, 0.92, 0.88, 0.86, 0.87, 0.88 and 0.72, respectively. The CTpre-based radiomics model was characterized by the best performance, with accuracy, sensitivity, and specificity of 0.86, 0.89, and 0.85, respectively. Conclusions The model based om CT radiomics has good predictive performance and application value in the discrimination of HAA from AP.
CHENG Yuanhua,LU Jing,HUA Rongrong等. Value of CT radiomics in discrimination of hypervascular adrenal adenoma from pheochromocytoma[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2025, 36(2): 154-158.
Fassnacht M, Tsagarakis S, Terzolo M, et al. European society of endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the european network for the study of adrenal tumors[J]. Eur J Endocrinol, 2023,189(1):G1-G42.
[2]
Aggarwal S, Prete A, Chortis V, et al. Pheochromocytomas most commonly present as adrenal incidentalomas: a large tertiary center experience[J]. J Clin Endocrinol Metab, 2023,109(1):e389-e396.
[3]
Bancos I, Prete A. Approach to the patient with adrenal incidentaloma[J]. The J of Clini End & Met, 2021,106(11):3331-3353.
[4]
Mete O, Asa S L, Gill A J, et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas[J]. Endocr Pathol, 2022,33(1):90-114.
[5]
Amin M B, Greene F L, Edge S B, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging[J]. CA: A Cancer Journal for Clinicians, 2017,67(2):93-99.
Yi X, Guan X, Zhang Y, et al. Radiomics improves efficiency for differentiating subclinical pheochromocytoma from lipid-poor adenoma: a predictive, preventive and personalized medical approach in adrenal incidentalomas[J]. EPMA J, 2018,9(4):421-429.
Aerts H J, Velazquez E R, Leijenaar R T, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach[J]. Nat Commun, 2014,5:4006.
Reiazi R, Abbas E, Famiyeh P, et al. The impact of the variation of imaging parameters on the robustness of Computed Tomography radiomic features: A review[J]. Computers in Bio Med, 2021,133:104400.
[13]
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: european society of endocrinology clinical practice guideline in collaboration with the european network for the study of adrenal tumors[J]. Eur J Endocrinol, 2016,175(2):G1-G34.
[14]
Lam A K. Update on Adrenal Tumours in 2017 world health organization (WHO) of endocrine tumours[J]. Endocr Pathol, 2017,28(3):213-227.
Gerson R, Tu W, Abreu-Gomez J, et al. Evaluation of the T2-weighted (T2W) adrenal MRI calculator to differentiate adrenal pheochromocytoma from lipid-poor adrenal adenoma[J]. Eur Radiol, 2022,32(12):8247-8255.
[18]
Niu Z, Wang J, Yang Y, et al. Risk prediction model establishment with tri-phasic CT image features for differential diagnosis of adrenal pheochromocytomas and lipid-poor adenomas: Grouping method[J]. Front Endocrinol (Lausanne), 2022,13:925577.
An Y Y, Yang G Z, Lin B, et al. Differentiation of lipid-poor adenoma from pheochromocytoma on biphasic contrast-enhanced CT[J]. Abdom Radiol (NY), 2021,46(9):4353-4361.
[21]
Yi X, Guan X, Chen C, et al. Adrenal incidentaloma: machine learning-based quantitative texture analysis of unenhanced CT can effectively differentiate sPHEO from lipid-poor adrenal adenoma[J]. J Cancer, 2018,9(19):3577-3582.
2025, Vol. 36 
